Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.
Biopharma industry success is always measured on late-stage trial readouts, but Roche is gearing up for an exceptional year of potential highs and lows, with no fewer than 10 pivotal results expected.
This mix of Phase II and Phase III readouts is largely coming from its oncology portfolio, including results by mid-year for its checkpoint inhibitor, Tecentriq (atezolizumab), and potential its first-in-class TIGIT drug,
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.
Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.
